Inovio Presents INO‑3107 Pro‑inflammatory CD4+ Activation in RRP; DMAb Safety and Investor Events

Inovio Brings DNA Immunotherapy Data to Spring Conferences

INO‑3107 in RRP: Pro‑inflammatory CD4+ T Cell Activation Reported

Inovio Pharmaceuticals is presenting new immunologic data for its DNA immunotherapy candidate INO‑3107 at the American Association for Cancer Research Immuno‑Oncology Conference on Feb. 18, saying the therapy induces activation and enrichment of pro‑inflammatory CD4+ T cells in blood and airways of patients who show clinical response. The poster, presented in Poster Session A, focuses on recurrent respiratory papillomatosis (RRP), a disorder caused by human papillomavirus (HPV) that produces recurrent benign tumors in the airway and can impact breathing and voice.

The company frames the T‑cell findings as evidence of a mechanistic immune response tied to clinical benefit, highlighting tissue and peripheral immune activation rather than antibody responses alone. Inovio positions these results as supportive of continued development of DNA‑based immunotherapies for HPV‑related diseases, arguing that enrichment of pro‑inflammatory CD4+ populations in affected airways may correlate with lesion control and symptomatic improvement in RRP patients.

While Inovio does not disclose full datasets in the announcement, the presentation of immunophenotyping from responders signals an effort to build translational evidence for INO‑3107 ahead of potential regulatory or clinical advancement decisions. The emphasis on localized airway immune changes underpins the company’s rationale for pursuing DNA medicines that aim to elicit targeted cellular immunity against virally driven lesions.

Conference Roadshow: DMAb Safety and Investor Webcasts

Inovio is also scheduled to present Phase 1 safety and pharmacokinetics data for SARS‑CoV‑2 DNA‑encoded monoclonal antibodies (DMAbs) in healthy adults at the Festival of Biologics in San Diego on March 4, and to appear in virtual investor fireside chats at the Oppenheimer Healthcare Life Sciences Conference on Feb. 25 and the Citizens Life Sciences Conference on March 10. The company says abstracts will be posted on its website after presentations and investor event replays will be available for 90 days.

Company Focus, Materials and Contacts

Inovio reiterates its strategic focus on developing and commercializing DNA medicines to treat and protect against HPV‑related diseases, cancer and infectious diseases. The company lists media and investor contacts, including Jennie Willson and Peter Vozzo of ICR Healthcare, and says management will hold one‑on‑one meetings during the conferences and make materials available via its events page.